Amino ceramide-like compounds and therapeutic methods of use
View Patent ↗The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
1. A compound of formula I:
a stereoisomer, a pharmaceutically acceptable salt or a mixture thereof, wherein
R 1 is a phenyl, a substituted phenyl group, a branched aliphatic group, or a 7-15 carbons long alkyl chain or a 7-15 carbons long alkenyl chain with a double bond next to the kernel;
R 2 is an alkyl group 6, 7, or 8 carbons long; and
R 3 is a pyrrolidine, azetidine, morpholine or piperidine, in which the nitrogen atom is attached to the kernel.
2. The compound of claim 1 , wherein R 1 is a phenyl group substituted with a functional group selected from the group consisting of a p-methoxy, hydroxyl, methylenedioxy, ethylenedioxy, trimethylenedioxy and cyclohexyl.
3. A method for inhibiting the growth of cancer cells in a patient, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of any of claim 1 or 2 , wherein said cancer cells are sensitive to said compound.
4. A method for treating a patient having a drug resistant tumor, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of any of claim 1 or 2 , wherein the cells of the tumor are sensitive to said compound.
5. A method for reducing tumor angiogenesis in a patient, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of any of claim 1 or 2 , wherein said angiogenesis is sensitive to said compound.
6. A method for treating a patient having a glyxosphingolipidosis disorder, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of any of claim 1 or 2 , wherein the glycosphingolipidos disorder is associated with the presence of glucosylceramide.
7. The method of claim 6 , wherein said glycosphingolipidos disorder is selected from the group consisting of Gaucher disease, Fabry disease, TaySachs, Sandhoff disease, and GM1 gangliosidosis.
8. A compound of formula I:
or a stereoisomer, pharmaceutically acceptable salt, or a mixture thereof, wherein
R 1 is a substituted or unsubstituted phenyl group, a branched aliphatic group, or a 7-15 carbons long alkyl chain or a 7-15 carbons long alkenyl chain with a double bond next to the kernel;
R 2 is an alkyl group 6, 7, or 8 carbons long; and
R 3 is pyrrolidine, in which the nitrogen atom is attached to the kernel.
9. The compound of claim 8 , wherein R 1 is a phenyl group substituted with a functional group selected from the group consisting of a p-methoxy, hydroxyl, methylenedioxy, ethylenedioxy, trimethylenedioxy and cyclohexyl.
10. A method for inhibiting the growth of cancer cells in a patient, comprising the step of administering to the patient a therapeutically effective amount of the compound of claim 8 , wherein said cancer cells are sensitive to said compound.
11. A method for treating a patient having a drug resistant tumor, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of claim 8 , wherein the cells of the tumor are sensitive to said compound.
12. A method for reducing tumor angiogenesis in a patient, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of claim 8 , wherein said angiogenesis is sensitive to said compound.
13. A method for treating a patient having a glycosphingolipidosis disorder, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of claim 8 , wherein the glycosphingolipidosis disorder is associated with the presence of glucosylceramide.
14. The method of claim 13 , wherein said glycosphingolipidosis disorder is selected from the group consisting of Gaucher disease, Fabry disease, TaySachs, Sandhoff disease, and GM1 gangliosidosis.